Abstract
Cancer immunotherapy orchestrates the immune system of the human body to fight against cancer cells. By doing this, it has revolutionized cancer treatment. Toxicities arising from dose-limit and low rates of patient response continue to be the major bottlenecks in clinical outcomes. The immune system has a close relationship with tumor. This leads to the combination of nanotechnology and immunotherapy. Nanotechnology can potentiate the efficacy of immunotherapy by enhancing the delivery and retention, and narrowing the toxicity of immunomodulation. In this regard, immunotherapy can combine with nanomedicine to give strategies that could lessen the side effects and improve clinical outcomes in patient populations. In this review, we explore and recapitulate recent advances in nanoparticle-based cancer immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmed KK, Geary SM, Salem AK (2016) Development and evaluation of biodegradable particles coloaded with antigen and the toll-like receptor agonist, pentaerythritol lipid a, as a cancer vaccine. J Pharm Sci 105(3):1173–1179. https://doi.org/10.1016/j.xphs.2015.11.042
Akhtar S, Benter I (2007) Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59(2–3):164–182. https://doi.org/10.1016/j.addr.2007.03.010
Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, Serada S, Fujimoto M, Naka T, Futaki S, Harashima H (2010) Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release 143(3):311–317. https://doi.org/10.1016/j.jconrel.2010.01.012
Ali AA, McCrudden CM, McCaffrey J, McBride JW, Cole G, Dunne NJ, Robson T, Kissenpfennig A, Donnelly RF, McCarthy HO (2017) DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. Nanomed Nanotechnol Biol Med 13(3):921–932. https://doi.org/10.1016/j.nano.2016.11.019
Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B (1991) Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 1992;12(1):19–31. https://www.ncbi.nlm.nih.gov/pubmed/1637781.
André F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L (2002) Tumor-derived exosomes: A new source of tumor rejection antigens. Vaccine 20(4):A28–A31. https://doi.org/10.1016/S0264-410X(02)00384-5
Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195(10):1303–1316. https://doi.org/10.1084/jem.20011624
Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F (2017a) Nanoparticles and targeted drug delivery in cancer therapy. Biomaterials 190:64–83. https://doi.org/10.1016/j.imlet.2017.07.015
Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F (2017b) Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett 190:64–83. https://doi.org/10.1016/j.imlet.2017.07.015
Bally H, Wong K, Wasan R (1999) Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291–315. https://doi.org/10.1016/s0169-409x(99)00034-4
Bhavsar MD, Amiji MM (2007) Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv 4(3):197–213. https://doi.org/10.1517/17425247.4.3.197
Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196(12):1627–1638. https://doi.org/10.1084/jem.20021598
Bracho-Sanchez E, Xia CQ, Clare-Salzler MJ, Keselowsky BG (2016) Micro and nano material carriers for immunomodulation. Am J Transplant 16(12):3362–3370. https://doi.org/10.1111/ajt.13878
Cabral H, Kataoka K (2014) Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 190:465–476. https://doi.org/10.1016/j.jconrel.2014.06.042
Carter RW, Thompson C, Reid DM, Wong SYC, Tough DF (2006) Preferential induction of CD4+ T Cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 177(4):2276–2284. https://doi.org/10.4049/jimmunol.177.4.2276
Cheever MA, Higano CS (2011) PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17(11):3520–3526. https://doi.org/10.1158/1078-0432.CCR-10-3126
Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012
Chen D, Koropatnick J, Jiang N, Zheng X, Zhang X, Wang H, Yuan K, Siu KS, Shunnar A, Way C, Min WP (2014a) Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma. J Immunother 37(2):123–134. https://doi.org/10.1097/CJI.0000000000000022
Chen M, Ouyang H, Zhou S, Li J, Ye Y (2014b) PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses. Cell Immunol 287(2):91–99. https://doi.org/10.1016/j.cellimm.2014.01.003
Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z (2016) Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun 7:13193. https://doi.org/10.1038/ncomms13193
Choi YH, Han H (2018) Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig 48:43–60. https://doi.org/10.1007/s40005-017-0370-4
Christian DA, Hunter CA (2012) Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy 4(4):425–441. https://doi.org/10.2217/imt.12.26
Clayton A, Mason MD (2009) Exosomes in tumour immunity. Curr Oncol 16(3):46–49. https://doi.org/10.3747/co.v16i3.367
Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z (2007) Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67(15):7458–7466. https://doi.org/10.1158/0008-5472.CAN-06-3456
Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z (2008) Human tumor-derived exosomes down-modulate nkg2d expression. J Immunol 180(11):7249–7258. https://doi.org/10.4049/jimmunol.180.11.7249
Cruz LJ, Tacken PJ, Fokkink R, Figdor CG (2011) The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Bomaterials 32(28):6791–6803. https://doi.org/10.1016/j.biomaterials.2011.04.082
Cruz LJ, Tacken PJ, Zeelenberg IS, Srinivas M, Bonetto F, Weigelin B, Eich C, de Vries IJ, Figdor CG (2014) Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism. Mol Pharm. 11(12):4299–4313. https://doi.org/10.1021/mp400717r
Daftarian P, Kaifer AE, Li W, Blomberg BB, Frasca D, Roth F, Chowdhury R, Berg EA, Fishman JB, Al Sayegh HA, Blackwelder P, Inverardi L, Perez VL, Lemmon V, Serafini P (2011) Peptide-conjugated PAMAM dendrimer as a universal platform for antigen presenting cell targeting and effective DNA-based vaccinations. Cancer Res 71(24):7452–7462. https://doi.org/10.1158/0008-5472.CAN-11-1766
Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, Coussens LM (2011) MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 17(17):5695–5704. https://doi.org/10.1158/1078-0432.CCR-10-3420
De Gregorio E, Rappuoli R (2014) From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 14(7):505–514. https://doi.org/10.1038/nri3694
Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, Nakamura K, Kawakami-Honda N, Goetsch L, Sawamura T, Bonnefoy J, Jeannin P (2002) Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17(3):353–362. https://doi.org/10.1016/S1074-7613(02)00388-6
Drake CG, Lipson EJ, Brahmer JR (2014) Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 11(1):24–37. https://doi.org/10.1038/nrclinonc.2013.208
Elhissi AM, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A (2012) Carbon nanotubes in cancer therapy and drug delivery. J Drug Deliv. https://doi.org/10.1155/2012/837327
Emami F, Mostafavi Yazdi SJ, Na DH (2019) Poly(lactic acid)/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery. J Pharm Investig 49:427–442. https://doi.org/10.1007/s40005-019-00443-1
Eppstein DA (1982) Altered pharmacologic properties of liposome-associated human interferon-alpha. II. J Interferon Res 2(1):117–125. https://doi.org/10.1089/jir.1982.2.117
Fan Y, Moon J (2015) Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines 3(3):662–685. https://doi.org/10.3390/vaccines3030662
Fang RH, Kroll AV, Zhang L (2015) Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy. Small 11(41):5483–5496. https://doi.org/10.1002/smll.201501284
Fayolle C, Sebo P, Ladant D, Ullmann A, Leclerc C (1996) In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol 156(12):4697–4706
Flanary S, Hoffman AS, Stayton PS (2009) Antigen delivery with poly(propylacrylic acid) conjugation enhances MHC-1 presentation and T-cell activation. Bioconj Chem 20(2):241–248. https://doi.org/10.1021/bc800317a
Garu A, Moku G, Gulla SK, Chaudhuri A (2016) Genetic immunization with in vivo dendritic cell-targeting liposomal DNA vaccine carrier induces long-lasting antitumor immune response. Mol Ther 24(2):385–397. https://doi.org/10.1038/mt.2015.215
Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M (2007) Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis 30(4):197–210. https://doi.org/10.1016/j.cimid.2007.01.002
Gould SJ, Raposo G (2013) As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. https://doi.org/10.3402/jev.v2i0.20389
Greening DW, Gopal SK, Xu R, Simpson RJ, Chen W (2015) Exosomes and their roles in immune regulation and cancer. Semin Cell Dev Biol 40:72–81. https://doi.org/10.1016/j.semcdb.2015.02.009
Guan X, Nishikawa M, Takemoto S, Ohno Y, Yata T, Takakura Y (2010) Injection site-dependent induction of immune response by DNA vaccine: comparison of skin and spleen as a target for vaccination. J Gene Med 12(3):301–309. https://doi.org/10.1002/jgm.1432
György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, Pállinger E, Pap E, Kittel A, Nagy G, Falus A, Buzás EI (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68(16):2667–2688. https://doi.org/10.1007/s00018-011-0689-3
Hamidi M, Azadi A, Rafiei P (2008) Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 60(15):1638–1649. https://doi.org/10.1016/j.addr.2008.08.002
Heo MB, Lim YT (2014) Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials 35(1):590–600. https://doi.org/10.1016/j.biomaterials.2013.10.009
Heo MB, Kim SY, Yun WS, Lim YT (2015) Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J Nanomed 10:5981–5993. https://doi.org/10.2147/IJN.S90104
Hoos A (2016) Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15(4):235–247. https://doi.org/10.1038/nrd.2015.35
Hu Q, Wu M, Fang C, Cheng C, Zhao M, Fang W, Chu PK, Ping Y, Tang G (2015) Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett 15(4):2732–2739. https://doi.org/10.1021/acs.nanolett.5b00570
Hwang I, Shen X, Sprent J (2003) Direct stimulation of naïve T cells by membrane vesicles from antigen-presenting cells: Distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci USA 100(11):6670–6675. https://doi.org/10.1073/pnas.1131852100
Hwang HS, Shin H, Han J, Na K (2018) Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy. J Pharm Investig 48:143–151. https://doi.org/10.1007/s40005-017-0377-x
Jadidi-Niaragh F, Atyabi F, Rastegari A, Kheshtchin N, Arab S, Hassannia H, Ajami M, Mirsanei Z, Habibi S, Masoumi F, Noorbakhsh F, Shokri F, Hadjati J (2017) CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J Control Release 246:46–59. https://doi.org/10.1016/j.jconrel.2016.12.012
Kabilova TO, Sen'kova AV, Nikolin VP, Popova NA, Zenkova MA, Vlassov VV, Chernolovskaya EL (2016) Antitumor and antimetastatic effect of small immunostimulatory RNA against B16 Melanoma in Mice. Mattei F, ed. PLoS ONE 11(3):e0150751. https://doi.org/10.1371/journal.pone.0150751
Kallen K-J, Theß A (2014) A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2(1):10–31. https://doi.org/10.1177/2051013613508729
Kalluri R (2016) The biology and function of exosomes in cancer. J Clin Investig 126(4):1208–1215. https://doi.org/10.1172/JCI81135
Kang H, Liu H, Zhang X, Yan J, Zhu Z, Peng L, Yang H, Kim Y, Tan W (2011) Photoresponsive DNA-cross-linked hydrogels for controllable release and cancer therapy. Langmuir 27(1):399–408. https://doi.org/10.1021/la1037553
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. https://doi.org/10.1056/NEJMoa1001294
Kapadia CH, Perry JL, Tian S, Luft JC, DeSimone JM (2015) Nanoparticulate immunotherapy for cancer. J Control Release 219:167–180. https://doi.org/10.1016/j.jconrel.2015.09.062
Karlsson J, Vaughan HJ, Green JJ (2018) Biodegradable polymeric nanoparticles for therapeutic cancer treatments. Annu Rev Chem Biomol Eng 9(1):105–127. https://doi.org/10.1146/annurev-chembioeng-060817-084055
Kauffman KJ, Webber MJ, Anderson DG (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 240:227–234. https://doi.org/10.1016/j.jconrel.2015.12.032
Kaufman HL, Disis ML (2004) Immune system versus tumor: Shifting the balance in favor of DCs and effective immunity. J Clin Investig 113(5):664–667. https://doi.org/10.1172/JCI21148
Kedar E, Gur H, Babai I, Samira S, Even-Chen S, Barenholz Y (2000) Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long- circulating liposomes. J Immunother 23(1):131–145. https://doi.org/10.1097/00002371-200001000-00016
Keller S, Sanderson MP, Stoeck A, Altevogt P (2006) Exosomes: From biogenesis and secretion to biological function. Immunol Lett 107(2):102–108. https://doi.org/10.1016/j.imlet.2006.09.005
Kim TH, Nah JW, Cho M-H, Park TG, Cho CS (2006) Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J Nanosci Nanotechnol 6(9–10):2796–2803. https://doi.org/10.1166/jnn.2006.434
Kim A, Miura Y, Ishii T, Mutaf OF, Nishiyama N, Cabral H, Kataoka K (2016) Intracellular delivery of charge-converted monoclonal antibodies by combinatorial design of block/homo polyion complex micelles. Biomacromol 17(2):446–453. https://doi.org/10.1021/acs.biomac.5b01335
Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J (2018) Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials 164:38–53. https://doi.org/10.1016/j.biomaterials.2018.02.034
Kokate RA, Chaudhary P, Sun X, Thamake SI, Maji S, Chib R, Vishwanatha JK, Jones HP (2016) Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Nanomedicine 11(5):479–494. https://doi.org/10.2217/nnm.15.213
Koshy ST, Mooney DJ (2016) Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol 40:1–8. https://doi.org/10.1016/j.copbio.2016.02.001
Kosmides AK, Sidhom J-W, Fraser A, Bessell CA, Schneck JP (2017) Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth. ACS Nano 11(6):5417–5429. https://doi.org/10.1021/acsnano.6b08152
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607):396–401. https://doi.org/10.1038/nature18300
Kwong B, Liu H, Irvine DJ (2011) Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials 32(22):5134–5147. https://doi.org/10.1016/j.biomaterials.2011.03.067
Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ (2013) Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res 73(5):1547–1558. https://doi.org/10.1158/0008-5472.CAN-12-3343
Lai C, Yu X, Zhuo H, Zhou N, Xie Y, He J, Peng Y, Xie X, Luo G, Zhou S, Zhao Y, Lu X (2014) Anti-tumor immune response of folate-conjugated chitosan nanoparticles containing the IP-10 gene in mice with hepatocellular carcinoma. J Biomed Nanotechnol 10(12):3576–3589. https://doi.org/10.1166/jbn.2014.2051
Lancaster GI, Febbraio MA (2005) Exosome-dependent trafficking of HSP70: A novel secretory pathway for cellular stress proteins. J Biol Chem 280(24):23349–23355. https://doi.org/10.1074/jbc.M502017200
Le QV, Choi J, Oh YK (2018) Nano delivery systems and cancer immunotherapy. J Pharm Investig 48(5):527–539. https://doi.org/10.1007/s40005-018-0399-z
Leach DG, Dharmaraj N, Piotrowski SL, Lopez-Silva TL, Lei YL, Sikora AG, Young S, Hartgerink JD (2018) STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials 163:67–75. https://doi.org/10.1016/j.biomaterials.2018.01.035
Lee WY, Asadujjaman M, Jee JP (2019) Long acting injectable formulations: the state of the arts and challenges of poly(lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal. J Pharm Investig 49(4):459–476. https://doi.org/10.1007/s40005-019-00449-9
Lei C, Liu P, Chen B, Mao Y, Engelmann H, Shin Y, Jaffar J, Hellstrom I, Liu J, Hellstrom KE (2010) Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc 132(20):6906–6907. https://doi.org/10.1021/ja102414t
Li SY, Liu Y, Xu CF, Shen S, Sun R, Du XJ, Xia JX, Zhu YH, Wang J (2016a) Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J Control Release 231:17–28. https://doi.org/10.1016/j.jconrel.2016.01.044
Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J, Li W, Wu G, Ren J, Wang Z, Zou W, Wang L (2016b) Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology 5(2):e1074374. https://doi.org/10.1080/2162402X.2015.1074374
Liang SY, Hu J, Xie YY, Zhou Q, Zhu YH, Yang XL (2016) A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice. Int J Nanomedicine 11:6753–6762. https://doi.org/10.2147/IJN.S122047
Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, Wu L, Yu S, Shi F, Li Y, Zhang L, Wang L, Feng S, Zhang Q, Peng Y, Wu Q, Liu C, Chang X, Yang L, Uemura Y, Yu X, Liu T (2017a) Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett 411:182–190. https://doi.org/10.1016/j.canlet.2017.09.022
Liu H, Chen L, Peng Y, Yu S, Liu J, Wu L, Zhang L, Wu Q, Chang X, Yu X, Liu T (2017b) Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy. Oncotarget 9(2):2887–2894. https://doi.org/10.18632/oncotarget.20812
Liu YJ, Dou XQ, Wang F, Zhang J, Wang XL, Xu GL, Xiang SS, Gao X, Fu J, Song HF (2017c) IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment. J Drug Target 25(3):275–283. https://doi.org/10.1080/1061186X.2016.1258569
Liu Z, Zhou C, Qin Y, Wang Z, Wang L, Wei X, Zhou Y, Li Q, Zhou H, Wang W, Fu YX, Zhu M, Liang W (2017d) Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell Discov 3:17007. https://doi.org/10.1038/celldisc.2017.7
Luo Z, Wang C, Yi H, Li P, Pan H, Liu L, Cai L, Ma Y (2015) Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Biomaterials 38:50–60. https://doi.org/10.1016/j.biomaterials.2014.10.050
Ma X, Williams RO (2018) Polymeric nanomedicines for poorly soluble drugs in oral delivery systems: an update. J Pharm Investig 48:61–75. https://doi.org/10.1007/s40005-017-0372-2
MacLachlan I, Cullis P (2005) Diffusible-PEG-lipid stabilized plasmid lipid particles. Adv Genet 53:157–188. https://doi.org/10.1016/S0065-2660(05)53006-2
Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J (2015) Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol 6:127. https://doi.org/10.3389/fimmu.2015.00127
Manandhar S, Kothandan VK, Oh J, Yoo SH, Hwang J, Hwang SR (2018) A pharmaceutical investigation into exosomes. J Pharm Investig 48:617–626. https://doi.org/10.1007/s40005-018-0391-7
Manjili HK, Malvandi H, Mousavi MS, Attari E, Danafar H (2018) In vitro and in vivo delivery of artemisinin loaded PCL–PEG–PCL micelles and its pharmacokinetic study. Artif Cells Nanomed Biotechnol 46(5):926–936. https://doi.org/10.1080/21691401.2017.1347880
Maude SL, Barrett D, Teachey DT, Grupp SA (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20(2):119–122. https://doi.org/10.1097/PPO.0000000000000035
Maurer N, Wong KF, Stark H, Louie L, McIntosh D, Wong T, Scherrer P, Semple SC, Cullis PR (2001) Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80(5):2310–2326. https://doi.org/10.1016/S0006-3495(01)76202-9
McNamara MA, Nair SK, Holl EK (2015) RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res. https://doi.org/10.1155/2015/794528
Mellman I, Steinman RM (2001) Dendritic cells: Specialized and regulated antigen processing machines. Cell 106(3):255–258. https://doi.org/10.1016/S0092-8674(01)00449-4
Menay F, Herschlik L, De Toro J, Cocozza F, Tsacalian R, Gravisaco MJ, Di Sciullo MP, Vendrell A, Waldner CI, Mongini C (2017) Exosomes isolated from ascites of T-Cell lymphoma-bearing mice expressing surface CD24 and HSP-90 induce a tumor-specific immune response. Front Immunol 8:286. https://doi.org/10.3389/fimmu.2017.00286
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ (2017) Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol 12(9):877–882. https://doi.org/10.1038/nnano.2017.113
Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H (2014) A new adjuvant delivery system “cyclic di-GMP/YSK05 liposome” for cancer immunotherapy. J Control Release 184(1):20–27. https://doi.org/10.1016/j.jconrel.2014.04.004
Moffett HF, Coon ME, Radtke S, Stephan SB, McKnight L, Lambert A, Stoddard BL, Kiem HP, Stephan MT (2017) Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers. Nat Commun 8(1):389. https://doi.org/10.1038/s41467-017-00505-8
Moon JJ, Huang B, Irvine DJ (2012) Engineering nano- and microparticles to tune immunity. Adv Mater 24(28):3724–3746. https://doi.org/10.1002/adma.201200446
Moore C, Kosgodage U, Lange S, Inal JM (2017) The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. Int J Cancer 141(3):428–436. https://doi.org/10.1002/ijc.30672
Morón G, Dadaglio G, Leclerc C (2004) New tools for antigen delivery to the MHC class I pathway. Trends Immunol 25(2):92–97. https://doi.org/10.1016/j.it.2003.11.008
Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3(1):9. https://doi.org/10.1186/1479-5876-3-9
Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL (2016) Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. https://doi.org/10.1038/srep20254
Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL (2012) Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1(7):1074–1083. https://doi.org/10.4161/onci.20897
Nathan C, Cunningham-Bussel A (2013) Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol 13(5):349–361. https://doi.org/10.1038/nri3423
Nitcheu Tefit J, Serra V (2011) Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev Vaccines 10(8):1207–1220. https://doi.org/10.1586/erv.11.84
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248–251. https://doi.org/10.1038/nature21428
Perinelli DR, Cespi M, Bonacucina G, Palmieri GF (2019) PEGylated polylactide (PLA) and poly (lactic-co-glycolic acid) (PLGA) copolymers for the design of drug delivery systems. J Pharm Investig 49:443–458. https://doi.org/10.1007/s40005-019-00442-2
Persano S, Guevara ML, Li Z, Mai J, Ferrari M, Pompa PP, Shen H (2017) Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials 125:81–89. https://doi.org/10.1016/j.biomaterials.2017.02.019
Petros RA, Desimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9(8):615–627. https://doi.org/10.1038/nrd2591
Phung DC, Nguyen HT, Tran P, Jin SG, Yong CS, Truong DH, Tran TH, Kim JO (2019) Combined hyperthermia and chemotherapy as a synergistic anticancer treatment. J Pharm Investig 49:519–526. https://doi.org/10.1007/s40005-019-00431-5
Qian Y, Qiao S, Dai Y, Xu G, Dai B, Lu L, Yu X, Luo Q, Zhang Z (2017) Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering rna to tumor-associated macrophages. ACS Nano 11(9):9536–9549. https://doi.org/10.1021/acsnano.7b05465
Qiu H, Min Y, Rodgers Z, Zhang L, Wang AZ (2017) Nanomedicine approaches to improve cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(5):e1456. https://doi.org/10.1002/wnan.1456
Rosenberg SA (2014) IL-2: The first effective immunotherapy for human cancer. J Immunol 192(12):5451–5458. https://doi.org/10.4049/jimmunol.1490019
Sayour EJ, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, Huang J, Sampson JH, Sanchez-Perez L, Flores C, Mitchell DA (2017) Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology 6(1):e1256527. https://doi.org/10.1080/2162402X.2016.1256527
Schwendener RA (2014) Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2(6):159–182. https://doi.org/10.1177/2051013614541440
Semple SC, Klimuk SK, Harasym TO, Hope MJ (2000) Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol 313:322–341. https://doi.org/10.1016/s0076-6879(00)13020-4
Shukla V, Dalela M, Vij M, Weichselbaum R, Kharbanda S, Ganguli M, Kufe D, Singh H (2017) Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. Nanomedicine 13(5):1833–1839. https://doi.org/10.1016/j.nano.2017.03.004
Silva JM, Zupancic E, Vandermeulen G, Oliveira VG, Salgado A, Videira M, Gaspar M, Graca L, Préat V, Florindo HF (2015) In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. J Control Release 198:91–103. https://doi.org/10.1016/j.jconrel.2014.11.033
Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E (2008) Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. Zimmer J, ed. PLoS ONE 3(10):e3377. https://doi.org/10.1371/journal.pone.0003377
Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, Boudaly S, Mécheri S (2003) Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. J Immunol 170(6):3037–3045. https://doi.org/10.4049/jimmunol.170.6.3037
Smith MJ, Brown JM, Zamboni WC, Walker NJ (2014) From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system. Toxicol Sci 138(2):249–255. https://doi.org/10.1093/toxsci/kfu005
Söderberg A, Barral AM, Söderström M, Sander B, Rosén A (2007) Redox-signaling transmitted in trans to neighboring cells by melanoma-derived TNF-containing exosomes. Free Radic Biol Med 43(1):90–99. https://doi.org/10.1016/j.freeradbiomed.2007.03.026
Song W, Musetti SN, Huang L (2017) Nanomaterials for cancer immunotherapy. Biomaterials 148:16–30. https://doi.org/10.1016/j.biomaterials.2017.09.017
Song H, Yang P, Huang P, Zhang C, Kong D, Wang W (2019) Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy. Theranostics 9(8):2299–2314. https://doi.org/10.7150/thno.30577
Steinman RM (1998) Dendritic cells and the control of immunity. Exp Hematol 26(8):681. https://doi.org/10.1038/32588
Stephan MT, Moon JJ, Um SH, Bersthteyn A, Irvine DJ (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 16(9):1035–1041. https://doi.org/10.1038/nm.2198
Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF (2016) In vitro and ex vivo strategies for intracellular delivery. Nature 538(7624):183–192. https://doi.org/10.1038/nature19764
Taylor DD, Gerçel-Taylor C (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92(2):305–311. https://doi.org/10.1038/sj.bjc.6602316
ten Hagen TLM, Seynhaeve ALB, van Tiel ST, Ruiter DJ, Eggermont AMM (2002) Pegylated liposomal tumor necrosis factor-α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma-bearing rats. Int J Cancer 97(1):115–120. https://doi.org/10.1002/ijc.1578
Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S (2001) Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166(12):7309–7318. https://doi.org/10.4049/jimmunol.166.12.7309
Théry C, Duban L, Segura E, Væron P, Lantz O, Amigorena S (2002) Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 3(12):1156–1162. https://doi.org/10.1038/ni854
Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9(8):581–593. https://doi.org/10.1038/nri2567
Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4(5):346–358. https://doi.org/10.1038/nrg1066
Toy R, Roy K (2016) Engineering nanoparticles to overcome barriers to immunotherapy. Bioeng Transl Med 1(1):47–62. https://doi.org/10.1002/btm2.10005
Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M, Minami M (2003) MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett 89(2–3):125–131. https://doi.org/10.1016/S0165-2478(03)00128-7
van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG (2004) Targeting dendritic cells with antigen-containing liposomes: A highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64(12):4357–4365. https://doi.org/10.1158/0008-5472.CAN-04-0138
van der Burg SH, Arens R, Ossendorp F, Van Hall T, Melief CJM (2016) Vaccines for established cancer: Overcoming the challenges posed by immune evasion. Nat Rev Cancer 16(4):219–233. https://doi.org/10.1038/nrc.2016.16
Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N (2009) Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα. Pockley G, ed. PLoS ONE. 4(3):e4942. https://doi.org/10.1371/journal.pone.0004942
Voshavar C, Meka RCR, Samanta S, Marepally S, Chaudhuri A (2017) Enhanced spacer length between mannose mimicking shikimoyl and quinoyl headgroups and hydrophobic region of cationic amphiphile increases efficiency of dendritic cell based dna vaccination: a structure–activity investigation. J Med Chem 60(4):1605–1610. https://doi.org/10.1021/acs.jmedchem.6b01556
Waeckerle-Men Y, Groettrup M (2005) PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 57(3):475–482. https://doi.org/10.1016/j.addr.2004.09.007
Wang C, Ye Y, Hu Q, Bellotti A, Gu Z (2017) Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook. Adv Mater 29(29):1606036. https://doi.org/10.1002/adma.201606036
Wang C, Wang J, Zhang X, Yu S, Wen D, Hu Q, Ye Y, Bomba H, Hu X, Liu Z, Dotti G, Gu Z (2018) In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aan3682
Wang J, Li S, Han Y, Guan J, Chung S, Wang C, Li D (2018) Poly(ethylene glycol)-polylactide micelles for cancer therapy. Front Pharmacol 9:202. https://doi.org/10.3389/fphar.2018.00202
Wilson JT, Keller S, Manganiello MJ, Cheng C, Lee CC, Opara C, Convertine A, Stayton PS (2013) pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 7(5):3912–3925. https://doi.org/10.1021/nn305466z
Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7(3):297–303. https://doi.org/10.1038/85438
Xu Z, Ramishetti S, Tseng Y-C, Guo S, Wang Y, Huang L (2013) Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release 172(1):259–265. https://doi.org/10.1016/j.jconrel.2013.08.021
Yamano T, Kaneda Y, Hiramatsu SH, Huang S, Tran AN, Giuliano AE, Hoon DS (2007) Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther 14(5):451–459. https://doi.org/10.1038/sj.cgt.7701035
Yang R, Xu J, Xu L, Sun X, Chen Q, Zhao Y, Peng R, Liu Z (2018) Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano 12(6):5121–5129. https://doi.org/10.1021/acsnano.7b09041
Yata T, Takahashi Y, Tan M, Nakatsuji H, Ohtsuki S, Murakami T, Imahori H, Umeki Y, Shiomi T, Takakura Y, Nishikawa M (2017) DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy. Biomaterials 146:136–145. https://doi.org/10.1016/j.biomaterials.2017.09.014
Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15(8):541–555. https://doi.org/10.1038/nrg3763
Yong SB, Chung JY, Song Y, Kim YH (2018) Recent challenges and advances in genetically-engineered cell therapy. J Pharm Investig 48(2):199–208. https://doi.org/10.1007/s40005-017-0381-1
Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C, Zhang HG (2007) Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178(11):6867–6875. https://doi.org/10.4049/jimmunol.178.11.6867
Yuba E, Kanda Y, Yoshizaki Y, Teranishi R, Harada A, Sugiura K, Izawa T, Yamate J, Sakaguchi N, Koiwai K, Kono K (2015) pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy. Biomaterials 67:214–224. https://doi.org/10.1016/j.biomaterials.2015.07.031
Zhang B (2010) CD73: A novel target for cancer immunotherapy. Cancer Res 70(16):6407–6411. https://doi.org/10.1158/0008-5472.CAN-10-1544
Zhang L, Tang Y, Akbulut H, Zelterman D, Linton P-J, Deisseroth AB (2003) An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci U S A. 100(25):15101–15106. https://doi.org/10.1073/pnas.2135379100
Zhang Z, Tsai P-C, Ramezanli T, Michniak-Kohn BB (2013a) Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5(3):205–218. https://doi.org/10.1002/wnan.1211
Zhang Z, Wang J, Chen C (2013b) Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging. Adv Mater 25(28):3869–3880. https://doi.org/10.1002/adma.201301890
Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ (2013) In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release 172(2):426–435. https://doi.org/10.1016/j.jconrel.2013.05.037
Zhou WZ, Kaneda Y, Huang SKS, Morishita R, Hoon DSB (1999) Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther 6(10):1768–1773. https://doi.org/10.1038/sj.gt.3300998
Zhu S, Niu M, O’Mary H, Cui Z (2013) Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm 10(9):3525–3530. https://doi.org/10.1021/mp400216r
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 4(5):594–600. https://doi.org/10.1038/nm0598-594
Zupančič E, Silva J, Videira MA, Moreira JN, Florindo HF (2014) Development of a novel nanoparticle-based therapeutic vaccine for breast cancer immunotherapy. Procedia Vaccinol 8:62–67. https://doi.org/10.1016/j.provac.2014.07.011
Acknowledgements
This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B07045240).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Asadujjaman, M., Cho, K.H., Jang, DJ. et al. Nanotechnology in the arena of cancer immunotherapy. Arch. Pharm. Res. 43, 58–79 (2020). https://doi.org/10.1007/s12272-020-01207-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01207-4